Additional Relevant Details

• Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets
• Menlo’s serlopitant for pruritus associated with prurigo nodularis (“PN”) complements Foamix’s existing portfolio and addresses a significant unmet medical need for a serious disease state
• Foamix’s sales and marketing infrastructure will provide meaningful leverage to potential launches for product candidates FMX103 for rosacea and Menlo’s serlopitant for pruritus associated with prurigo nodularis
• Strong pipeline with several meaningful near-term catalysts
• Strong combined balance sheet with cash through H1 2021
• Foamix shareholders expected to own approximately 59% and Menlo shareholders approximately 41% of the combined company, subject to adjustment